FDA Continues to Crack Down on Unapproved Stem Cell Clinics

May 14, 2018

(Medscape) – The US Food and Drug Administration (FDA) is seeking permanent injunctions to stop two US stem cell clinics from marketing stem cell products without the agency’s approval and for “significant deviations” from current good manufacturing requirements. The actions against the clinics, which are based in Florida and California, are part of a comprehensive approach to the oversight of regenerative medicinal products, the FDA said.

Recommended Reading